Mikhail Blagosklonny: различия между версиями

Версия от 11:14, 22 октября 2024

Languages:

Mikhail Blagosklonny was a scientist who studied cancer and aging. He died in October 2024. He was an adjunct faculty member at Roswell Park Comprehensive Cancer Center in Buffalo, New York.

Career

Blagosklonny earned both his M.D. in internal medicine and his PhD in experimental medicine and cardiology from the First Pavlov State Medical University of St. Petersburg.[citation needed] He was appointed associate professor of medicine at New York Medical College, Valhalla, NY in 2002 before taking a position as a senior scientist at Ordway Research Institute (Albany, New York). Blagosklonny held this position until 2009, when he was appointed professor of oncology at Roswell Park Comprehensive Cancer Center.

Blagosklonny's research interests include cancer and targeted cancer therapies that protect normal cells from damage, as well as the underlying mechanisms of aging (biogerontology) and anti-aging drugs. Roswell Park Comprehensive Cancer Center lists Blagosklonny as holding "Adjunct Faculty" and "Cell Stress Biology" positions with them.

Rapamycin and aging

Blagosklonny has formulated a hypothesis about the possible role of TOR signaling in aging and cancer and proposed using rapamycin, a popular cancer drug as a possible treatment for life extension.[4] He advocates for rapamycin use in longevity research.

Editorial activities

Blagosklonny is editor-in-chief of Aging,^[1] Cell Cycle,^[2] and Oncotarget.^[3] In addition, he is associate editor of Cancer Biology & Therapy^[4] and a member of the editorial board of Cell Death & Differentiation.^[5]

The peer review process employed by Oncotarget has been criticized by Jeffrey Beall,^[6] a university librarian and expert on predatory open access publishing, who also included Oncotarget and Aging on his list of "potential, possible, or probable predatory scholarly open-access journals"^[7] in July 2015.^[6] Further reports on Beall's blog suggest that the substandard peer review processes for these journals are used by their respective editors-in-chief to entice prospective authors to include references to Blagosklonny's own publications in their articles (following the peer review), thereby raising his personal citation impact.^[8]

Health

Blagosklonny announced that in January 2023 he was diagnosed with numerous metastases of lung cancer in his brain.^[9] He died in October 2024 at the age of 63.^[10]

References

↑ {{{last1}}}, {{{first1}}} ({{{date}}}). "Editorial Board". {{{website}}}. "{{{quote}}}"
↑ {{{last1}}}, {{{first1}}} ({{{date}}}). "Editorial Board". {{{website}}}. "{{{quote}}}"
↑ {{{last1}}}, {{{first1}}} ({{{date}}}). "Editorial Board". {{{website}}}. "{{{quote}}}"
↑ {{{last1}}}, {{{first1}}} ({{{date}}}). "Editorial board". {{{website}}}. "{{{quote}}}"
↑ {{{last1}}}, {{{first1}}} ({{{date}}}). "About the journal". {{{website}}}. "{{{quote}}}"
↑ ^6,0 ^6,1 Beall, Jeffrey (19 April 2016). "Oncotarget's Peer Review is Highly Questionable". Scholarly Open Access. "{{{quote}}}"
↑ Beall, Jeffrey (2016-11-20). "LIST OF STANDALONE JOURNALS: Potential, possible, or probable predatory scholarly open-access journals". Scholarly Open Access. "{{{quote}}}"
↑ {{{last1}}}, {{{first1}}} (6 December 2016). "Mikhail Blagosklonny's Journal Aging: A Review". Scholarly Open Access. "{{{quote}}}"
↑ {{{last1}}}, {{{first1}}} (26 October 2023). "My battle with cancer". {{{website}}}. "{{{quote}}}"
↑ {{{last1}}}, {{{first1}}} ({{{date}}}). "Passing of Dr. Misha Blagoskonny". {{{website}}}. "{{{quote}}}"

Mikhail Blagosklonny on Wikipedia

[1] {{{last1}}}, {{{first1}}} ({{{date}}}). "Editorial Board". {{{website}}}. "{{{quote}}}"

[2] {{{last1}}}, {{{first1}}} ({{{date}}}). "Editorial Board". {{{website}}}. "{{{quote}}}"

[3] {{{last1}}}, {{{first1}}} ({{{date}}}). "Editorial Board". {{{website}}}. "{{{quote}}}"

[4] {{{last1}}}, {{{first1}}} ({{{date}}}). "Editorial board". {{{website}}}. "{{{quote}}}"

[5] {{{last1}}}, {{{first1}}} ({{{date}}}). "About the journal". {{{website}}}. "{{{quote}}}"

[Beall-6] 6,0 ^6,1 Beall, Jeffrey (19 April 2016). "Oncotarget's Peer Review is Highly Questionable". Scholarly Open Access. "{{{quote}}}"

[7] Beall, Jeffrey (2016-11-20). "LIST OF STANDALONE JOURNALS: Potential, possible, or probable predatory scholarly open-access journals". Scholarly Open Access. "{{{quote}}}"

[8] {{{last1}}}, {{{first1}}} (6 December 2016). "Mikhail Blagosklonny's Journal Aging: A Review". Scholarly Open Access. "{{{quote}}}"

[9] {{{last1}}}, {{{first1}}} (26 October 2023). "My battle with cancer". {{{website}}}. "{{{quote}}}"

[10] {{{last1}}}, {{{first1}}} ({{{date}}}). "Passing of Dr. Misha Blagoskonny". {{{website}}}. "{{{quote}}}"

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

@@ Строка 10: / Строка 10: @@
 ==Rapamycin and aging==
-Blagosklonny has formulated a hypothesis about the possible role of [[TOR signaling]] in aging and cancer and proposed using [[rapamycin]], a popular cancer drug as a possible treatment for life extension.<ref>{{cite journal |first=David|last=Stipp|title=A New Path to Longevity |journal=[[Scientific American]] |date=2011 |volume=306|issue=1|doi=10.1038/scientificamerican0112-32 |pages=32–39|pmid=22279832|bibcode=2011SciAm.306f..32S}}</ref> He advocates for rapamycin use in longevity research.<ref>{{cite news |url=https://www.bloomberg.com/news/features/2015-02-12/does-a-real-anti-aging-pill-already-exist-|title = Does a Real Anti-Aging Pill Already Exist? Inside Novartis's push to produce the first legitimate anti-aging drug, Business Week, 2015|newspaper = Bloomberg.com|date = 12 February 2015|accessdate = November 20, 2016}}</ref>
+Blagosklonny has formulated a hypothesis about the possible role of TOR signaling in aging and cancer and proposed using rapamycin, a popular cancer drug as a possible treatment for life extension.[4] He advocates for rapamycin use in longevity research.
 == Editorial activities==